Phentermine

Known as: alpha,alpha-Dimethylphenethylamine, Phentermine [Chemical/Ingredient], Phenterminum 
A natural monoamine alkaloid derivative and a sympathomimetic stimulant with appetite suppressant property. Phentermine, which was part of the Fen… (More)
National Institutes of Health

Related topics

Related topics

38 relations

Narrower (11)

2-methyl-2-nitro-1-phenylpropane4-iodophentermineAdipex-PDuromine
(More)
24 HR Phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule [Qsymia]Appetite Suppression [PE]ArteriosclerosisChild
(More)

Broader (5)

Adrenergic AgentsAmphetamineAppetite DepressantsCentral Nervous System Stimulants
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
OBJECTIVE A 28-week, randomized, controlled trial compared the combination of phentermine and topiramate extended-release (PHEN… (More)
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled…
BACKGROUND Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases… (More)
Is this relevant?
2010
2010
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Preclinical evidence suggests that pharmacotherapy for obesity using combinations of agents targeted at distinct regulatory… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing… (More)
  • table I
  • table II
  • table III
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
Familial primary pulmonary hypertension is a rare autosomal dominant disorder that has reduced penetrance and that has been… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
BACKGROUND Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Valvular heart disease associated with fenfluramine-phentermine.
 
Is this relevant?
1997
1997
Valvular heart disease associated with fenfluramine-phentermine.
BACKGROUND Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration… (More)
Is this relevant?
1996
1996
Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy Volunteers
Recent clinical reports indicate that combined administration of phentermine and fenfluramine may have useful effects in the… (More)
Is this relevant?